Prevention of pneumococcal infection with vaccines: An evolving story

JAMA

Volumn 307, Issue 8, 2012, Pages 847-849

  Shapiro, Eugene D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; 13 VALENT PNEUMOCOCCAL VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; 23 VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE;

BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG TREATMENT FAILURE; EDITORIAL; EVIDENCE BASED MEDICINE; GOLD STANDARD; HIGH RISK POPULATION; HUMAN; IMMUNOASSAY; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; LUNG BIOPSY; MORBIDITY; MORTALITY; NONHUMAN; PNEUMOCOCCAL INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUANTITATIVE ANALYSIS; RISK REDUCTION; SENSITIVITY ANALYSIS; SENSITIVITY AND SENSIBILITY; SEROTYPE; VACCINE PRODUCTION; ECONOMICS; NOTE; STREPTOCOCCUS PNEUMONIA; VACCINATION;

HUMANS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; VACCINATION;

EID: 84857424095     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.194     Document Type: Editorial

References (18)

1. Wright AE, Parry Morgan W, Colebrook L, Dodgson RW.Observations on prophylactic inoculation against pneumococcus infection and on the results which have been achieved by it. Lancet. 1914;183:1-10,87-95.
2. Austrian R. A brief history of pneumococcal vaccines. Drugs Aging. 1999; 15(suppl 1):1-10. (Pubitemid 30071861)
3. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59(34): 1102-1106.
4. Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis. 2008;47(10):1328-1338.
5. Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2011;2(1):e00309-e00310.
6. Meissner HC, Pickering LK. Control of disease attributable to Haemophilus influenzae type b and the National Immunization Program. Pediatrics. 2002;110(4):820-823.
7. Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics. 2010;125(3):429-436.
8. Centers for Disease Control and Prevention (CDC). Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children: Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010;59(9):258-261.
9. FDA expands use of Prevnar 13 vaccine for people ages 50 and older [news release]. US Food and Drug Administration. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm285431.htm. Accessed January 27, 2012.
10. Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA. 2012;307(8):804-812.
11. Rozenbaum MH, Hak E, van der Werf TS, Postma MJ. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands. Clin Ther. 2010;32(8):1517-1532.
12. Patel R, Stoykova B, Lloyd AC, Willingham J, Hollingsworth R. The cost-effectiveness of the new pneumococcal 13-valent conjugate vaccine (PCV13) for childhood and adult vaccination in the UK. Value Health. 2009;12:A428.
13. Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1997;46(RR-08):1-24.
14. Bates JH, Campbell GD, Barron AL, et al. Microbial etiology of acute pneumonia in hospitalized patients. Chest. 1992;101(4):1005-1012.
15. Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21(9):810-815.
16. Hak E, Grobbee DE, Sanders EA, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med. 2008;66(9):378-383.
17. Butler JC, Bosshardt SC, Phelan M, et al. Classical and latent class analysis evaluation of sputum polymerase chain reaction and urine antigen testing for diagnosis of pneumococcal pneumonia in adults. J Infect Dis. 2003;187(9):1416-1423. (Pubitemid 36549687)
18. Pilishvili T, Lexau C, Farley MM, et al Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32-41.